Share on StockTwits

Kamada (NASDAQ:KMDA) posted its quarterly earnings results on Thursday. The company reported ($0.23) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.02) by $0.21, American Banking & Market News reports. The company had revenue of $15.80 million for the quarter, compared to the consensus estimate of $17.17 million.

KMDA has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Kamada from a “neutral” rating to an “underperform” rating in a research note on Thursday, August 7th. They now have a $6.60 price target on the stock. On the ratings front, analysts at Oppenheimer initiated coverage on shares of Kamada in a research note on Tuesday, July 8th. They set a “market perform” rating on the stock. Finally, analysts at Oppenheimer downgraded shares of Kamada from an “outperform” rating to a “market perform” rating in a research note on Friday, May 16th.

Shares of Kamada (NASDAQ:KMDA) opened at 7.18 on Thursday. Kamada has a 52-week low of $6.34 and a 52-week high of $17.95. The stock’s 50-day moving average is $6.89 and its 200-day moving average is $11.75. The company’s market cap is $249.1 million.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.